期刊文献+

小儿肺热咳喘口服液防治甲型H1N1流感病毒感染免疫低下小鼠的研究 被引量:7

Preventative and Therapeutical Effect of Xiaoer Feire Kechuan Oral Solution on Immunocompromised Mice Infected by Influenza Virus A (H1N1)
原文传递
导出
摘要 目的:评价小儿肺热咳喘口服液对免疫低下小鼠感染甲型H1N1流感病毒的防治作用。方法:ICR小鼠sc环磷酰胺造成免疫低下,以甲型H1N1流感病毒滴鼻感染造成肺炎模型,造模同时及造模前ig 20,10,5 mL·kg-1小儿肺热咳喘口服液4 d后观察肺部炎症、计算肺指数,死亡率和生命延长率,Real-time RT-PCR法检测肺组织中病毒载量,酶联免疫法检测血清中免疫因子的含量。结果:小儿肺热咳喘口服液治疗性给药或预防性给药后能明显降低流感病毒FM1株和PR8株感染后免疫低下小鼠的肺指数、降低死亡率、延长平均存活天数、显著降低小鼠肺组织中的病毒载量,明显升高小鼠血清中CD4/CD8的比值。结论:小儿肺热咳喘口服液对甲型H1N1流感病毒感染免疫低下小鼠造成的病毒性肺炎具有明显的防治作用。 Objective:To evaluate the preventative and therapeutical effect of Xiaoer Feire Kechuan oral solution on the immunocompromised mice infected by influenza virus A(H1N1).Method: ICR mice were injected cyclophosphamide to establish immunocompromised mice model,at the same day,the mice were infected by influenza A(H1N1) by nasal drops.The lung index,death rate,death protection rate and life prolongation were observed;The virus load in lungs was detected by real-time RT-PCR and the level of immune factors in blood serum were detected by ELISA.Result: With preventative and therapeutical treatment of Xiaoer Feire Kechuan oral solution,the lung index,death rate and the virus load in lung tissues of immunocompromised mice which were infected by influenza virus FM1 strain and PR8 strain decreased significantly,while the life time of immunocompromised mice was prolonged by the oral solution and CD4 /CD8 ratio in serum increased significantly.Conclusion: Xiaoer Feire Kechuan oral solution could inhibit virus pneumonia in immunocompromised mice caused by influenza virus A(H1N1)significantly.
出处 《中国实验方剂学杂志》 CAS 北大核心 2010年第17期172-176,共5页 Chinese Journal of Experimental Traditional Medical Formulae
基金 国家重大新药创制项目(2009ZX09301-005-007) 中国中医科学院中药研究所自主选题项目(ZZ20090103)
关键词 小儿肺热咳喘口服液 流感病毒 免疫低下小鼠 病毒性肺炎 Xiaoer Feire Kechuan oral solution influenza virus immunocompromised mice viral pneumonia
  • 相关文献

参考文献9

二级参考文献11

  • 1陈奇,中药药理研究方法学,1993年
  • 2贺双滕,湖南中医学院学报,1991年,11卷,4期,55页
  • 3马淑清,黑龙江中医学院学报,1990年,1卷,22页
  • 4Dr. Scott Weingarten MD,Howard Staniloff MD,Mark Ault MD,Peggy Miles MD,Mark Bamberger MD,Richard D. Meyer MD. Do hospital employees benefit from the influenza vaccine?[J] 1988,Journal of General Internal Medicine(1):32~37
  • 5Monto AS,Fleming DM,Henry D,et al.Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections[].The Journal of Infectious Diseases.1999
  • 6McNicholl IR,McNicholl JJ.Neuraminidase inhibitors: zanamivir and oseltamivir[].Annals of Pharmacotherapy.2001
  • 7Hayden FG,Atmar RL,Schilling M,et al.Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza[].The New England Journal of Medicine.1999
  • 8Nicholson KG,Aoki FY,Osterhaus AD,et al.Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlledtrial.Neuraminidase Inhibitor Flu Treatment Investigator Group[].The Lancet.2000
  • 9Treanor JJ,Hayden FG,Vrooman PS,et al.Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial.US Oral Neuraminidase Study Group[].The Journal of The American Medical Association.2000
  • 10Kim CU,Lew W,Williams MA,et al.Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site[].Journal of the American Chemical Society.1997

共引文献95

同被引文献63

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部